Maternal health startup Oli names medtech veteran to board
Oli appoints medtech leader Colby Holtshouse to guide regulatory approval in Australia and the US.
Oli develops wireless technology to predict pregnancy problems like postpartum bleeding before they happen. The startup has raised 25 million dollars and recently finished its final clinical trial.
The trial included 1,000 mothers across seven Australian and US hospitals. Holtshouse brings strong expertise.
She led sales of a postpartum bleeding treatment at Organon. She now leads May Health, a fertility-technology company.
At Oli, she will guide the company through regulatory approval in Australia and the US. The appointment signals the startup is moving from testing to the approval phase.
This is a critical step for any medtech company.
- 25 million dollars
- Funding raised
- 1,000 mothers
- Trial participants
- Seven Australian and US hospitals
- Trial sites
- Tara Croft
- CEO
Why it mattersHoltshouse's experience strengthens Oli's chances of winning health regulator approval. The technology could prevent serious maternal complications.
AustraliaIf approved, the device would bring a new pregnancy safety tool to Australian hospitals and maternity wards, filling a gap in maternal monitoring.
✓ Claims checked against the source. checked 4 h ago
Open this story in InSnip →
